Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| WD 40 COWDFC · Entity 4262 | Director | February 05, 2026 | February 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
WD 40 CO
Report date February 05, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,898 |
Reported balance
After 2026-02-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-05 · Purchase · Acquired 424 · Balance 6,898 F1: Represents: (i) 1,275 shares acquired via stock purchases by Reporting Owner, and (ii) 5,623 vested RSUs treated as common stock equivalents. Following termination of Reporting Person's service as a director, vested RSUs will be settled with Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents: (i) 1,275 shares acquired via stock purchases by Reporting Owner, and (ii) 5,623 vested RSUs treated as common stock equivalents. Following termination of Reporting Person's service as a director, vested RSUs will be settled with Issuer's common stock.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RESMED INC
Report date June 30, 2023 · Filed June 30, 2023
Section 16 reporting ended · disclosed 2023-06-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 89,729 |
Reported balance
Holding disclosure · report date 2023-06-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 89,729 |
SEQUENOM INC
Report date September 07, 2016 · Filed September 07, 2016
Section 16 reporting ended · disclosed 2016-09-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 1
1 source rowRow 1 · 2016-09-07 · Other · Disposed 112,969 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.11 · Expires 2026-06-14 | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-09-07 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").
F2: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2017 Filed Feb 6, 2017 20:22 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,365 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-004529 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,280 Underlying: ResMed Common Stock · 6,365 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:22 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 6,365 | $67.16 | $427,473.40 |
DisclosureSEC source: 0001140361-17-004529 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,896 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:22 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,365 | $27.58 | $175,546.70 |
DisclosureSEC source: 0001140361-17-004529 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:01 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,365 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-000356 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,645 Underlying: ResMed Common Stock · 6,365 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:01 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 6,365 | $61.95 | $394,311.75 |
DisclosureSEC source: 0001140361-17-000356 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,896 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:01 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,365 | $27.58 | $175,546.70 |
DisclosureSEC source: 0001140361-17-000356 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 21:50 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,365 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-16-088908 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,010 Underlying: ResMed Common Stock · 6,365 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 21:50 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 6,365 | $60.00 | $381,900.00 |
DisclosureSEC source: 0001140361-16-088908 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,896 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 21:50 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,365 | $27.58 | $175,546.70 |
DisclosureSEC source: 0001140361-16-088908 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 16, 2016 Filed Nov 17, 2016 23:54 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 37,244 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001140361-16-087135 · doc1.xml · derivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,244 Underlying: ResMed Common Stock · 37,244 shares Expires 2023-11-16 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2017, 2018 and 2019. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 19:09 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 1,140 | $59.85 | $68,229.00 |
DisclosureSEC source: 0001140361-16-086279 · doc1.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,896 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 19:09 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 1,194 | $59.85 | $71,460.90 |
DisclosureSEC source: 0001140361-16-086279 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,036 F2 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 19:09 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 1,043 | $59.85 | $62,423.55 |
DisclosureSEC source: 0001140361-16-086279 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,273 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/13/2013. Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 16:40 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,033 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-16-084988 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 6,033 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 16:40 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 6,033 | $57.79 | $348,647.07 |
DisclosureSEC source: 0001140361-16-084988 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,273 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $57.73 to $57.81. The price reported above reflects the weighted average sale price. Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 16:40 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,033 | $33.70 | $203,312.10 |
DisclosureSEC source: 0001140361-16-084988 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 212 shares of ResMed stock purchased on October, 31 2016, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 21:30 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,000 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-16-081739 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,033 Underlying: ResMed Common Stock · 6,000 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 21:30 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 6,000 | $63.95 | $383,718.00 |
DisclosureSEC source: 0001140361-16-081739 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,061 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $63.64 to $64.28. The price reported above reflects the weighted average sale price. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 21:30 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,000 | $33.70 | $202,200.00 |
DisclosureSEC source: 0001140361-16-081739 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 07, 2016 Filed Sep 7, 2016 17:48 UTC | SEQUENOM INC SQNM · Entity 182543 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $1.11 | Not disclosed |
DisclosureSEC source: 0001209191-16-140451 · doc4.xml · derivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-06-14 F2 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F2 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 07, 2016 Filed Sep 7, 2016 17:48 UTC | SEQUENOM INC SQNM · Entity 182543 | OtherCommon Stock | 112,969 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-140451 · doc4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 16:43 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,000 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-16-079165 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,033 Underlying: ResMed Common Stock · 6,000 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 16:43 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 6,000 | $67.18 | $403,050.00 |
DisclosureSEC source: 0001140361-16-079165 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,061 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $66.99 to $67.36. The price reported above reflects the weighted average sale price. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 16:43 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,000 | $33.70 | $202,200.00 |
DisclosureSEC source: 0001140361-16-079165 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.